Allison Rosenthal
YOU?
Author Swipe
View article: CTNI-60. PROMISING EFFICACY SIGNAL IN SECONDARY CNS LYMPHOMA PATIENTS TREATED WITH EMAVUSERTIB AND IBRUTINIB
CTNI-60. PROMISING EFFICACY SIGNAL IN SECONDARY CNS LYMPHOMA PATIENTS TREATED WITH EMAVUSERTIB AND IBRUTINIB Open
Secondary central nervous system lymphoma (SCNSL) is defined as the diagnosis of CNS lymphoma diagnosed concurrently with systemic lymphoma or after prior treatment. Due to the poor prognosis associated with SCNSL, the lack of randomized t…
View article: Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access
Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access Open
Autologous Chimeric antigen receptor (CAR) T-cell therapies have demonstrated substantial efficacy in patients with relapsed or refractory hematologic malignancies; however, their implementation has been constrained by regulatory barriers.…
View article: Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis Open
View article: Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin’s lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial Protocol
Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin’s lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial Protocol Open
View article: Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma
Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma Open
Although follicular lymphoma (FL) typically follows an indolent course, patients with FL who experience early events such as transformation or progression have increased risk of death related to lymphoma. The FL24Cx is an algorithm based o…
View article: Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access
Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access Open
Autologous Chimeric antigen receptor (CAR) T-cell therapies have demonstrated substantial efficacy in patients with relapsed or refractory hematologic malignancies; however, their implementation has been constrained by regulatory barriers.…
View article: Hepatosplenic T-cell lymphoma, αβ type, presenting in an elderly patient status post indolent B-cell lymphoma treatment: report of a case and review of the literature
Hepatosplenic T-cell lymphoma, αβ type, presenting in an elderly patient status post indolent B-cell lymphoma treatment: report of a case and review of the literature Open
Hepatosplenic T-cell lymphoma (HSTL) is a rare and aggressive mature T-cell lymphoma characterized by hepatosplenic involvement. It usually occurs de novo in adolescents and young adults (AYA) and has been most commonly reported in the set…
View article: Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study
Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study Open
View article: 105 | INTERIM RESULTS OF TANDEM CD20‐CD19‐DIRECTED NON‐CRYOPRESERVED CAR‐T CELLS—ZAMTOCABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
105 | INTERIM RESULTS OF TANDEM CD20‐CD19‐DIRECTED NON‐CRYOPRESERVED CAR‐T CELLS—ZAMTOCABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA Open
View article: Refractory marginal zone lymphoma uncovers activated phosphoinositide 3-kinase delta syndrome type 1 (APDS1)
Refractory marginal zone lymphoma uncovers activated phosphoinositide 3-kinase delta syndrome type 1 (APDS1) Open
Activated PI3K delta syndrome is a rare primary combined immunodeficiency that can present with lymphoma. Genetic testing of patients with atypical lymphoma may reveal an underlying immunodeficiency and improve clinical outcomes.
View article: Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival
Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival Open
Background Hypomagnesemia has been correlated with inferior outcomes in patients with large B cell lymphoma (LBCL) undergoing stem cell transplants. As T-cell and myeloid cell dysfunction have been associated with low magnesium conditions,…
View article: Risk of lymphoid malignancy associated with cancer predisposition genes
Risk of lymphoid malignancy associated with cancer predisposition genes Open
View article: Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies
Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies Open
No specific echocardiographic variables predicted the development of CRS ≥ 2, and therefore the mechanism leading to hemodynamic decompensation and producing worsening hypoxia and hypotension could be multifactorial and not directly cardia…
View article: Primary Central Nervous System Lymphoma Tumor Biopsies Show Heterogeneity in Gene Expression Profiles and Genetic Subtypes
Primary Central Nervous System Lymphoma Tumor Biopsies Show Heterogeneity in Gene Expression Profiles and Genetic Subtypes Open
Background Primary central nervous system lymphoma (PCNSL) is clinically challenging due to its location and small biopsy size, leading to a lack of comprehensive molecular and biologic description. We previously demonstrated that 91% of P…
View article: Hypomagnesemia in Large B cell Lymphoma patients receiving CAR T cell therapy correlates with immune dysregulation and decreased PFS: results from the ZUMA-1 trial and Mayo Clinic cohort
Hypomagnesemia in Large B cell Lymphoma patients receiving CAR T cell therapy correlates with immune dysregulation and decreased PFS: results from the ZUMA-1 trial and Mayo Clinic cohort Open
Background Hypomagnesemia has been correlated with inferior outcomes in patients with large B cell lymphoma (LBCL) undergoing stem cell transplants. As T-cell and myeloid cell dysfunction have been associated with low magnesium conditions,…
View article: Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma Open
Many therapies are available for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥ 2 lines of therapy, albeit with scant evidence on the comparative effectiveness of these therapies. This study used i…
View article: Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management Open
View article: Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy Open
Unirradiated patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) who undergo anti-CD19 chimeric antigen receptor T-cell therapy (CART) have a predominant localized pattern of relapse, the significance of which is heig…
View article: Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy
Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy Open
The standard of care (SOC) for fit patients with relapsed diffuse large B-cell lymphoma (DLBCL) ≥12 months after completing frontline therapy is salvage chemotherapy (ST) followed by autologous stem cell transplant (ASCT). However, this st…
View article: Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas
Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas Open
The emergence of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment paradigm for R/R B-cell NHLs. However, challenges persist in accurately evaluating treatment response and detecting early rela…
View article: Tailoring Radiation Therapy for Patients With Limited Cutaneous T Cell Lymphoma: Preliminary Clinical Experience With Subtotal Skin Electron Therapy
Tailoring Radiation Therapy for Patients With Limited Cutaneous T Cell Lymphoma: Preliminary Clinical Experience With Subtotal Skin Electron Therapy Open
This analysis demonstrated that treatment of CTCL patients with low disease burden with STSEBT results in similar overall response and time to progression compared to treatment with TSEBT.
View article: Fine-Tuning Low-Dose Total Skin Electron Therapy for Optimal Management of Cutaneous T-Cell Lymphoma: A Comparative Analysis of Regimens
Fine-Tuning Low-Dose Total Skin Electron Therapy for Optimal Management of Cutaneous T-Cell Lymphoma: A Comparative Analysis of Regimens Open
View article: Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy Open
This case-control study examines the incidence and risks of myeloid neoplasms in adults treated for B-cell lymphoproliferative disorders or multiple myeloma.
View article: Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy
Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy Open
Chimeric antigen receptor T-cell (CAR-T) therapy is the new standard of care in fit patients with refractory or early relapsed diffuse large B-cell lymphoma (DLBCL). However, there may still be a role for salvage chemotherapy (ST) and auto…
View article: Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving <scp>bendamustine–rituximab</scp>
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving <span>bendamustine–rituximab</span> Open
Summary Mantle cell lymphoma (MCL) is clinically and biologically heterogeneous. While various prognostic features have been proposed, none currently impact therapy selection, particularly in older patients, for whom treatment is primarily…
View article: Physiologic<sup>18</sup>F-FDG Uptake in Brown Adipose Tissue and Lactating Breast in a Patient with Hodgkin Lymphoma
Physiologic<sup>18</sup>F-FDG Uptake in Brown Adipose Tissue and Lactating Breast in a Patient with Hodgkin Lymphoma Open
We present the case of a young woman with Hodgkin lymphoma exhibiting physiologic 18F-FDG uptake in brown adipose tissue and lactating breast on consecutive 18F-FDG PET/CT scans. Both entities are common imaging inter…
View article: Disparities in care and outcomes for adolescent and young adult lymphoma patients
Disparities in care and outcomes for adolescent and young adult lymphoma patients Open
Though survival outcomes among adolescents and young adults (AYAs) with lymphoma have improved over the last three decades, socially vulnerable populations including non‐White, low‐income, and publicly insured groups continue to trail behi…
View article: Primary cutaneous diffuse large B-cell lymphoma, leg type, presenting as subcutaneous nodules: Case series and comparison of treatment outcomes
Primary cutaneous diffuse large B-cell lymphoma, leg type, presenting as subcutaneous nodules: Case series and comparison of treatment outcomes Open
View article: POSTER: ABCL-673 Single Cell Analysis Reveals Immune Dysfunction in Large B-Cell Lymphoma (LBCL) Patients With Hypomagnesemia Receiving Axi-Cel: Results from ZUMA-1 Trial and Mayo Clinic Cohort
POSTER: ABCL-673 Single Cell Analysis Reveals Immune Dysfunction in Large B-Cell Lymphoma (LBCL) Patients With Hypomagnesemia Receiving Axi-Cel: Results from ZUMA-1 Trial and Mayo Clinic Cohort Open
View article: P1359: TUMOR-SPECIFIC, T-CELL-TARGETING MICRORNA IS ASSOCIATED WITH CART CELL FAILURE IN B CELL MALIGNANCIES
P1359: TUMOR-SPECIFIC, T-CELL-TARGETING MICRORNA IS ASSOCIATED WITH CART CELL FAILURE IN B CELL MALIGNANCIES Open
Topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research Background: Despite the promising efficacy of anti-CD19 chimeric antigen receptor T-cell therapy (CART19) for the treatment of B-cell malign…